Biosimilars

Brain Cancer

Neoadjuvant HER2+

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immunotherapy in GU Cancers

Immunotherapy in Lung Cancer

Immunotherapy in Melanoma

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Oncology Nursing News

Pediatric Oncology

Special Reports in Personalized Cancer Care

Precision Medicine in Oncology®

Sarcomas/TGCT

Supportive Care

OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Sifting Through Data in Lung Cancer and Leukemia: Drs Levy and Saint Fleur

The addition of pelabresib and ruxolitinib (Jakafi) led to a significant and durable reduction in splenomegaly, among other improvements, vs ruxolitinib alone in JAK inhibitor–naive patients with myelofibrosis.

Updated MANIFEST-2 Data With Pelabresib/Ruxolitinib Support Paradigm Shift in Myelofibrosis

Ponatinib generated long-term efficacy and displayed manageable safety in chronic-phase chronic myeloid leukemia harboring a T315I mutation.

Ponatinib Showcases Long-Term Efficacy, Safety in CP-CML With T315I Mutations

Viktor Grünwald, MD, PhD, on patterns of progression and subsequent therapy for patients with advanced RCC treated during the phase 3 CLEAR trial.

Dr Grünwald on Examining Progression Patterns for Lenvatinib Plus Pembrolizumab in Advanced RCC

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Biomarker Consortium

Subscribe

Videos

 
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles


Gina Mauro is your lead editorial contact for 

. She joined the company in 2015 and has held various positions on 

; she is also the on-air correspondent for 

. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: 

The COMBI-AD dataset is the longest follow-up to date of adjuvant treatment for patients with stage III melanoma. 

Up to 10 Years of Follow-Up Uphold Survival Benefit With Adjuvant Dabrafenib/Trametinib in Stage III Melanoma 

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

Twitter

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Post-Conference Perspectives: Recent Advances in the Management of Chronic GvHD

Preet M. Chaudhary, MD, PhD and Noah Merin, MD, PhD discuss the chronic graft versus host disease treatment landscape, covering first- and second-line treatments and emergent trial data.

Preet M. Chaudhary, MD, PhD and Noah Merin, MD, PhD review how chronic GvHD is diagnosed, the different types of chronic GvHD, and key risk factors for the disease.

The Chronic GvHD Landscape:  Risk Factors and Diagnosis 

Expert clinicians discuss first-line treatment methodologies for chronic GvHD, with a focus on tailoring treatments to the patient. 


First-line Treatment for Patients with Chronic GvHD

Dr. Merin defines steroid refractory chronic GvHD, explains how to determine when patients become steroid-refractory and discusses treatment approach for this population. 


Defining and Managing Steroid Refractory Chronic GvHD

Dr. Chaudhary introduces data supporting the use of ruxolitinib as a first-line option in patients with steroid-refractory chronic GvHD. 


Role of Ruxolitinib in Steroid-Refractory Chronic GvHD

Dr. Merin describes the mechanisms of action of ruxolitinib, ibrutinib, and belumosudil and shares clinical pearls for community oncologists on methods for achieving response with these agents.

Understanding Mechanisms of Action: Ruxolitinib, Ibrutinib, and Belumosudil

A brief review of the key efficacy data for two treatment options, Ibrutinib and Belumosudil, in patients with chronic GvHD.

Key Efficacy Data of Ibrutinib and Belumosudil in Steroid-Refractory Chronic GvHD Patients

Discussion centered around real-world data following the approval of ruxolitinib as a treatment option for patients with chronic GvHD as well as discussing  treatment selection for patients with chronic GvHD, with special consideration for treatment sequencing.

Real World Data on the Use of Ruxolitinib and Treatment Selection in chronic GvHD

Dr. Chaudhary and Dr. Merin discuss potential areas for exploration and unmet needs in the chronic GvHD treatment landscape. 

Future Directions in Chronic GvHD

First-line Treatment for Patients with Chronic GvHD

EP: 1.The Chronic GvHD Landscape: Risk Factors and Diagnosis

EP: 2.First-line Treatment for Patients with Chronic GvHD

EP: 3.Defining and Managing Steroid Refractory Chronic GvHD

EP: 4.Role of Ruxolitinib in Steroid-Refractory Chronic GvHD

EP: 5.Understanding Mechanisms of Action: Ruxolitinib, Ibrutinib, and Belumosudil

EP: 6.Key Efficacy Data of Ibrutinib and Belumosudil in Steroid-Refractory Chronic GvHD Patients

EP: 7.Real World Data on the Use of Ruxolitinib and Treatment Selection in chronic GvHD

EP: 8.Future Directions in Chronic GvHD

Latest Conference Coverage